Karolinska Development publishes prospectus relating to set off issue
(Thomson Reuters ONE) -
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER
RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE
PRESS RELEASE.
STOCKHOLM - March 17, 2017. Karolinska Development AB's (publ) ("Karolinska
Development" or the "Company") prospectus relating to a new issue of B-shares to
the Company's convertible holders, with payment by set-off (the "Set-off Issue")
was approved by and registered with the Swedish Financial Supervisory Authority
on March 16, 2017.
The prospectus relating to Karolinska Development's Set-off Issue is now
available at the Company's website (www.karolinskadevelopment.com) and the SEB
Emissioner's website (www.sebgroup.se/prospectuses).
Karolinska Development has retained Advokatfirman Lindahl as legal adviser in
connection with the Set-off Issue. SEB Emissioner acts as issuing agent in
connection with the Set-off Issue.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden(at)karolinskadevelopment.com
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The Company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a
proven track record as company builders and with access to a strong global
network.
For more information, please visit www.karolinskadevelopment.com.
Important information
The information in this press release does not constitute an offer to acquire,
subscribe for or otherwise trade in shares or other securities in Karolinska
Development. Any invitation to the persons concerned to subscribe for shares in
Karolinska Development will only be made through the prospectus referred to in
this press release.
This press release may not be released, published or distributed, directly or
indirectly, in or into the United States, Australia, Canada, Japan, New Zealand,
South Africa or any other jurisdiction where such action is wholly or partially
subject to legal restrictions or where such action would require additional
prospectuses, registrations or other actions in addition to those required under
Swedish laws and regulations. Nor may the information in this press release be
forwarded, reproduced or disclosed in a manner that contravenes such
restrictions or would entail such requirements. Failure to comply with this
instruction may result in a violation of applicable securities laws.
No shares have been or will be registered under the U.S. Securities Act of
1933, as amended ("Securities Act"), or securities legislation in any state or
other jurisdiction in the United States, and may not be offered or sold,
directly or indirectly, in or into the United States, except pursuant to an
available exemption from the registration requirements of the Securities Act and
in compliance with the securities laws of any state or other jurisdiction of the
United States.
This press release may contain forward-looking statements which reflect
Karolinska Development's current view on future events and financial and
operational development. The words "intend", "estimate", "expect", "may",
"plan", "anticipate" or similar expressions regarding indications or predictions
of future developments or trends and which are not statements based on
historical facts constitute forward-looking information. Although Karolinska
Development believes that these statements are based on reasonable assumptions
and expectations, Karolinska Development cannot give any assurances that such
statements will materialize. Forward-looking statements are in its nature
involved with both known and unknown risks and uncertainties, since it is
depending on future events and circumstances. Forward-looking statements do not
constitute any representations and warranties, and the outcome could differ
materially from the information set out in the forward-looking statements.
This information is information that Karolinska Development AB (publ) (Nasdaq
Stockholm: KDEV) is obligated to make public pursuant to the Financial
Instruments Trading Act (1991:980). The information was submitted for
publication, through the agency of Jim Van heusden, on March 17, 2017 at 08:00
(CET).
Karolinska Development release of prospectus (ENG):
http://hugin.info/143071/R/2088443/788300.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.03.2017 - 08:02 Uhr
Sprache: Deutsch
News-ID 530877
Anzahl Zeichen: 6697
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development publishes prospectus relating to set off issue"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
